Sharp Therapeutics (TSXV:SHRX) Research & Development: C$4.91 Mil (TTM As of Dec. 2025)


TSXV:SHRX Sharp Therapeutics Corp TSXV:SHRX
15 GF Score
Price C$0.91
View Full Analysis

What is Sharp Therapeutics Research & Development?

Sharp Therapeutics TSXV:SHRX -9.00% 15 Research & Development is C$4.91 Mil as of Dec. 2025. GuruFocus rates TSXV:SHRX with a GF Score™ of 15/100.

Research & Development is the aggregate amount of research and development expenses during the year. Sharp Therapeutics's Research & Development for the three months ended in Dec. 2025 was C$1.35 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was C$4.91 Mil.

Sharp Therapeutics  (TSXV:SHRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sharp Therapeutics Research & Development Related Terms

Sharp Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics Research & Development Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
2.32 2.98 4.87

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only 0.77 1.28 1.34 0.95 1.35
TSXV:SHRX
15GF Score
Sharp Therapeutics Corp TSXV:SHRX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$4.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$4.91 Mil mean?
Sharp Therapeutics (TSXV:SHRX) has a Research & Development of C$4.91 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Sharp Therapeutics and its competitors.
Is Sharp Therapeutics' Research & Development too high?
Sharp Therapeutics' current Research & Development is C$4.91 Mil. Overall, Sharp Therapeutics has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Research & Development compare to VRTX and REGN?
Sharp Therapeutics' Research & Development of C$4.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current Research & Development is C$4.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Research & Development of C$4.91 Mil. The current Research & Development is C$4.91 Mil. Sharp Therapeutics' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Research & Development is C$4.91 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
15GF Score

Get the complete analysis for TSXV:SHRX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.91
Price